Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 27;62(9):e00590-18.
doi: 10.1128/AAC.00590-18. Print 2018 Sep.

In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam

A Van Dalem #  1 , M Herpol #  2 , F Echahidi  2 , C Peeters  3 , I Wybo  2 , E De Wachter  4 , P Vandamme  3 , D Piérard  2
Affiliations

In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam

A Van Dalem et al. Antimicrob Agents Chemother. .

Abstract

We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012. The highest susceptibility (82%) was found for trimethoprim-sulfamethoxazole. Eighty-one and 63% of all BCC strains were susceptible to ceftazidime-avibactam and ceftolozane-tazobactam, respectively. For temocillin, ceftazidime, piperacillin-tazobactam, and meropenem, at least 50% of the strains were susceptible. B. stabilis seems to be more resistant than other BCC species.

Keywords: Burkholderia cepacia complex; ceftazidime-avibactam; ceftolozane-tazobactam; cystic fibrosis; in vitro susceptibility.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. De Smet B, Mayo M, Peeters C, Zlosnik JE, Spilker T, Hird TJ, LiPuma JJ, Kidd TJ, Kaestli M, Ginther JL, Wagner DM, Keim P, Bell SC, Jacobs JA, Currie BJ, Vandamme P. 2015. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. Int J Syst Evol Microbiol 65:2265–2271. doi:10.1099/ijs.0.000251. - DOI - PubMed
    1. Isles A, Maclusky I, Corey M, Gold R, Prober C, Fleming P, Levison H. 1984. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 104:206–210. doi:10.1016/S0022-3476(84)80993-2. - DOI - PubMed
    1. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM, Jarvis WR. 1985. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 107:382–387. doi:10.1016/S0022-3476(85)80511-4. - DOI - PubMed
    1. Murray S, Charbeneau J, Marshall BC, LiPuma JJ. 2008. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 178:363–371. doi:10.1164/rccm.200712-1834OC. - DOI - PubMed
    1. Poirel L, Rodriguez-Martinez JM, Plesiat P, Nordmann P. 2009. Naturally occurring class A β-lactamases from the Burkholderia cepacia complex. Antimicrob Agents Chemother 53:876–882. doi:10.1128/AAC.00946-08. - DOI - PMC - PubMed

Publication types

MeSH terms